Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles

Biomaterials

Volumn 34, Issue 20, 2013, Pages 4818-4830

  Kuo, Yung Chih ^a   Ko, Hsing Fu ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

83 14 Monoclonal antibody; Brain; Endothelium; Phagocytosis; Saquinavir; Solid lipid nanoparticle

Indexed keywords

ENDOTHELIUM; ENTRAPMENT EFFICIENCY; MONOCLONAL ANTIBODIES (MAB); PHAGOCYTOSIS; SAQUINAVIR; SOLID LIPID NANOPARTICLE (SLN); SOLID LIPID NANOPARTICLES; TARGETING DELIVERIES;

ANTIGEN-ANTIBODY REACTIONS; BIOCHEMISTRY; BRAIN; ENDOTHELIAL CELLS; GRAFTING (CHEMICAL); MOLECULAR BIOLOGY; NANOPARTICLES; PARTICLE SIZE; ZETA POTENTIAL;

MONOCLONAL ANTIBODIES;

83 14 MONOCLONAL ANTIBODY; DRUG CARRIER; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; NITROGEN; PALMITIC ACID; POLOXAMER; SAQUINAVIR; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BIOAVAILABILITY; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CELL NUCLEUS; CELL VIABILITY; CHEMICAL MODIFICATION; CONCENTRATION (PARAMETERS); CYTOTOXICITY TEST; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; LIPID COMPOSITION; MICROVASCULAR ENDOTHELIAL CELL; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL; ZETA POTENTIAL;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; BRAIN; CELL DEATH; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; ENDOTHELIAL CELLS; HUMANS; KINETICS; LIPIDS; MICE; MICROSCOPY, FLUORESCENCE; MICROVESSELS; NANOPARTICLES; PERMEABILITY; PHOTOELECTRON SPECTROSCOPY; SAQUINAVIR; STATIC ELECTRICITY; SURFACE-ACTIVE AGENTS;

EID: 84876090501     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.013     Document Type: Article

References (60)

1. Levy J.A. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 2009, 23:147-160.
2. de Silva T.I., Cotten M., Rowland-Jones S.L. HIV-2: the forgotten AIDS virus. Trends Microbiol 2008, 16:588-595.
3. Noble S., Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. AIDS 1996, 52:93-112.
4. Fitzsimmons M.E., Collins J.M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4-Potential contribution to high first-pass metabolism. Drug Metab Dispos 1997, 25:256-266.
5. Bauer B., Hartz A.M.S., Fricker G., Miller D.S. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med 2005, 230:118-127.
6. Bachmeier C.J., Spitzenberger T.J., Elmquist W.F., Miller D.W. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res 2005, 22:1259-1268.
7. Kuo Y.C., Lu C.H. Modulation of efflux proteins by electromagnetic field for delivering azidothymidine and saquinavir into the brain. Colloids Surf B 2012, 91:291-295.
8. Muller R.H., Mehnert W., Lucks J.S., Schwarz C., zur Muhlen A., Weyhers H., et al. Solid lipid nanoparticles (SLN)-an alternative colloidal drug carrier system for controlled drug delivery. Eur J Pharm 1995, 41:62-69.
9. Storm G., Belliot S.O., Daemen T., Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliver Rev 1995, 17:31-48.
10. Troster S.D., Muller U., Kreuter J. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int J Pharm 1990, 61:85-100.
11. Xiong X.Y., Tam K.C., Gan L.H. Synthesis and thermally responsive properties of novel pluronic F87/polycaprolactone (PCL) block copolymers with short PCL blocks. J Appl Polym Sci 2006, 100:4163-4172.
12. Wittemann A., Azzam T., Eisenberg A. Biocompatible polymer vesicles from biamphiphilic triblock copolymers and their interaction with bovine serum albumin. Langmuir 2007, 23:2224-2230.
13. Yang L., Guo C., Jia L., Xie K., Shou Q., Liu H. Fabrication of biocompatible temperature- and pH-responsive magnetic nanoparticles and their reversible agglomeration in aqueous milieu. Ind Eng Chem Res 2010, 49:8518-8525.
14. Lee S.H., Lee J.E., Baek W.Y., Lim J.O. Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistant Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo. J Control Release 2004, 96:1-7.
15. Dhal P.K., Huval C.C., Holmes-Farley S.R. Functional polymers as human therapeutic agents. Ind Eng Chem Res 2005, 44:8593-8604.
16. ® block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002, 54:759-779.
17. Kreuter J., Alyautdin R.N., Kharkevich D.A., Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995, 674:171-174.
18. Schroder U., Sabel B.A. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res 1996, 710:121-124.
19. Gessner A., Olbrich C., Schroder W., Kayser O., Muller R.H. The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int J Pharm 2001, 214:87-91.
20. Ramge P., Unger R.E., Oltrogge J.B., Zenker D., Begley D., Kreuter J., et al. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur J Neurosci 2000, 12:1931-1940.
21. Kuo Y.C., Chen H.H. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J Drug Target 2010, 18:447-456.
22. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002, 10:317-325.
23. Kuo Y.C., Kuo C.Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int J Pharm 2008, 351:271-281.
24. Pardridge W.M. Vector-mediated drug delivery to the brain. Adv Drug Deliver Rev 1999, 36:299-321.
25. Prigent S.A., Stanley K.K., Siddle K. Identification of epitopes on the human insulin receptor reacting with rabbit polyclonal antisera and mouse monoclonal antibodies. J Biol Chem 1990, 265:9970-9977.
26. Boado R.J., Zhang Y.F., Zhang Y., Pardridge W.M. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng 2007, 96:381-391.
27. Kuo Y.C., Wang C.C. Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia. Colloids Surf B 2013, 101:101-105.
28. Kuo Y.C., Yu H.W. Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(γ-glutamic acid). Int J Pharm 2011, 416:365-375.
29. Kuo Y.C., Chen I.C. Evaluation of surface charge density and surface potential by electrophoretic mobility for solid lipid nanoparticles and human brain-microvascular endothelial cells. J Phys Chem B 2007, 111:11228-11236.
30. Kuo Y.C., Lu C.H. Expression of P-glycoprotein and multidrug resistance-associated protein on human brain-microvascular endothelial cells with electromagnetic stimulation. Colloids Surf B 2012, 91:57-62.
31. Kuo Y.C., Lu C.H. Effect of human astrocytes on the characteristics of human brain-microvascular endothelial cells in the blood-brain barrier. Colloids Surf B 2011, 86:225-231.
32. Kuo Y.C., Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int J Pharm 2006, 327:160-169.
33. Kuo Y.C., Su F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 2007, 340:143-152.
34. Shi L.J., Li Z., Yu L., Jia H., Zheng L.Q. Effects of surfactants and lipids on the preparation of solid lipid nanoparticles using double emulsion method. J Disper Sci Technol 2011, 32:254-259.
35. Eisner M.D., Jeelani S.A.K., Windhab E.J. Stability of foams containing proteins, fat particles and nonionic surfactants. Chem Eng Sci 2007, 62:1974-1987.
36. Heurtault B., Saulnier P., Pech B., Proust J.E., Benoit J.P. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003, 24:4283-4300.
37. Kuo Y.C., Shih K.H., Yang J.T. Capillary electrophoresis of bone marrow stromal cells with the uptake of heparin-functionalized poly(lactide-co-glycolide) nanoparticles during differentiation towards neurons. Electrophoresis 2010, 31:315-323.
38. Kovacevic A., Savic S., Vuleta G., Muller R.H., Keck C.M. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm 2011, 406:163-172.
39. Bilati U., Allemann E., Doelker E. Poly(D, L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method-processing and formulation issues for enhanced entrapment efficiency. J Microencapsul 2005, 22:205-214.
40. Kuo Y.C., Chen H.H. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int J Pharm 2009, 365:206-213.
41. Bunjes H., Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev 2007, 59:379-402.
42. Kuo Y.C., Liang C.T. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 2011, 32:3340-3350.
43. Jones C.F., Grainger D.W. In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev 2009, 61:438-456.
44. Kuo Y.C., Chung J.F. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Colloids Surf B 2011, 83:299-306.
45. Zhang L.Y., Hu Y., Jiang X.Q., Yang C.Z., Lu W., Yang Y.H. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release 2004, 96:135-148.
46. Alyautdin R.N., Kharkevich D.A., Petrov V.E., Langer K., Berthold A., Kreuter J. Delivery of lopermide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997, 14:325-328.
47. Muller R.H., Maassen S., Weyhers H., Specht F., Lucks J.S. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm 1996, 138:85-94.
48. ® block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002, 82:189-212.
49. Kuo Y.C., Lu C.H. Regulation of endocytosis into human brain-microvascular endothelial cells by inhibition of efflux proteins. Colloids Surf B 2011, 87:139-145.
50. Callahan M.K., Williams K.A., Kivisakk P., Pearce D., Stins M.F., Ransohoff R.M. CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J Neuroimmunol 2004, 153:150-157.
51. Kuo Y.C., Lin C.W. Impact of arginine-modified solid lipid nanoparticles on the membrane charge of human brain-microvascular endothelial cells. Colloids Surf B 2009, 72:201-207.
52. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001, 47:65-81.
53. Alyautdin R.N., Tezikov E.B., Ramge P., Kharkevich D.A., Begley D.J., Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 1998, 15:67-74.
54. Borchard G., Audus K.L., Shi F., Kreuter J. Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int J Pharm 1994, 110:29-35.
55. Pardridge W.M., Kang Y.S., Buciak J.L., Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transctosis through the blood-brain barrier. Pharm Res 1995, 12:807-816.
56. Walus L.R., Pardridge W.M., Starzyk R.M., Friden P.M. Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier following conjugation to anti-transferrin receptor antibodies. J Pharmacol Exp Ther 1996, 277:1067-1075.
57. Duffy K.R., Pardridge W.M. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 1987, 420:32-38.
58. Duffy K.R., Pardridge W.M., Rosenfeld R.G. Human blood-brain barrier insulin-like growth factor receptor. Metabolism 1988, 37:136-140.
59. Golden P.L., Maccagnan T.J., Pardridge W.M. Human blood-brain barrier leptin receptor: binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997, 99:14-18.
60. Kuo Y.C., Lin P.I., Wang C.C. Targeting nevirapine delivery across human brain microvesscular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles. Nanomedicine 2011, 6:1011-1026.